Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tranzyme Takes On Diabetic Gastroparesis With Novel Ghrelin Agonist

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With Phase II efficacy data in hand for the I.V. version of its ghrelin agonist, Tranzyme Pharma has launched a Phase II safety and efficacy study of an oral outpatient formulation in patients with diabetic gastroparesis

You may also be interested in...

Metoclopramide Gets Boxed Warning, REMS, For Movement Disorder Risk

FDA issued a class-wide requirement Feb. 26 for metoclopramide-containing products to gain a boxed warning and Risk Evaluation and Mitigation Strategy to address the gastrointestinal drug's associated risk of tardive dyskinesia

From Verus to Meritage: A Biotech Prototype for Tough Economic Times

Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.

Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says

Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts